Literature DB >> 2155286

Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts.

L Kinnunen1, A Huovilainen, T Pöyry, T Hovi.   

Abstract

A panel of nine neutralizing monoclonal antibodies was used to analyse the antigenic properties of 188 plaque-purified type 3 poliovirus strains from 17 faecal specimens, derived from eight people during a 2 month observation period. Most poliovirus specimens consisted of a mixture of antigenically distinct variants and the composition of the mixture was found to change between sequential specimens in many individuals, indicating antigenic evolution. Thirty-five strains representing different antigenic patterns were selected for partial sequencing of genomic RNA. Mutations leading to amino acid substitutions, as well as silent mutations, were seen at and close to the known antigenic sites. The frequency of silent mutations was used to estimate the evolutionary potential of the virus. The largest difference in silent changes between strains isolated from one person was 0.8%, which corresponds to a minimum of about 60 mutations per genome within a period of 3 weeks. The observed incidence of silent mutations between isolates from different persons was usually between 0.8 and 2%. These figures agree with the previously reported overall mutation rates of poliovirus, determined by other methods.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155286     DOI: 10.1099/0022-1317-71-2-317

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Authors:  G V Gavrilin; E A Cherkasova; G Y Lipskaya; O M Kew; V I Agol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus.

Authors:  J C de la Torre; C Giachetti; B L Semler; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Authors:  J J Holland; J C de la Torre; D K Clarke; E Duarte
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies.

Authors:  M A Martínez; C Carrillo; F González-Candelas; A Moya; E Domingo; F Sobrino
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Molecular characterization of wild-type polioviruses isolated in Greece during the 1996 outbreak in Albania.

Authors:  Zaharoula Kyriakopoulou; Christine Kottaridi; Evaggelos Dedepsidis; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Panayotis Markoulatos
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  RNA virus quasispecies populations can suppress vastly superior mutant progeny.

Authors:  J C de la Torre; J J Holland
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Hyper-antigenic variation occurs with human rhinovirus type 17.

Authors:  L J Patterson; V V Hamparian
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Evolutionary analysis of the picornavirus family.

Authors:  M J Rodrigo; J Dopazo
Journal:  J Mol Evol       Date:  1995-04       Impact factor: 2.395

10.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.